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Abstract 1 
Recent advances in genotyping technology and insights into disease mechanisms have increased 2 
interest in the genetics of cardiovascular disease. Several candidate genes involved in 3 
cardiovascular diseases were identified from studies using animal models, and translation of 4 
these findings to human disease is an exciting challenge. There is a trend towards large-scale 5 
genome-wide association studies that are subject to strict quality criteria with regard to both 6 
genotyping and phenotyping. We will review some of the strategies developed to translate 7 
findings from experimental models to human disease and outline the need for optimizing global 8 
approaches to analyze such results. Findings from ongoing studies will be interpreted in the 9 
context of disease pathways instead of the more traditional focus on single genetic variants. 10 
 3 
Introduction 1 
The pathogenesis of cardiovascular diseases involves a complex interplay between 2 
environmental and genetic factors. The relative contribution of these factors to development of 3 
disease and manifestation of symptoms differs not only between disease entities but also between 4 
individual patients. Severe phenotypes can be observed as a result of mutations in single genes 5 
such as in monogenic forms of hypertension, but the majority of cardiovascular diseases involve 6 
mutations in a larger number of genes [1,2]. We will provide an overview of strategies to 7 
examine the genetic basis of human cardiovascular disease. This will include a translational 8 
approach from rodent to human genetics and recent findings from large-scale genotyping 9 
projects in man. 10 
In recent years, we have witnessed substantial progress in unravelling the genetic determinants 11 
of cardiovascular disease. Better understanding of pathophysiological principles and recent 12 
genome-wide association studies (GWAS) have identified robust candidate genes involved in 13 
cardiovascular disease. Rapidly evolving tools such as chip-based genotyping technology [3,4] 14 
have enabled the genotyping of hundreds of thousands of single nucleotide polymorphisms 15 
(SNPs) within a short timeframe and at a fraction what a single SNP would have costed just a 16 
few years ago. This innovation has facilitated genetic studies in large cohorts in multicentre and 17 
multinational collaborations [5-11]. These advances in human population genetics have been 18 
complemented by a significant progress in our understanding of molecular genetics ranging from 19 
design of animal models to discovery of key elements of gene regulation. 20 
The recent publication of results of GWAS into seven common diseases by the Wellcome Trust 21 
Case Control Consortium (WTCCC) [5] has elicited unprecedented interest in the genetic basis 22 
of human disease not only in the scientific community but also in the wider public arena. This 23 
interest has been driven by a number of reasons. First, WTCCC was the first large-scale genome 24 
scan using dense SNP markers across the genome. Previous genome scans were limited by the 25 
 4 
inability to genotype a large number of markers and therefore used fewer but highly polymorphic 1 
markers in the form of microsatellites. In WTCCC the large number of SNPs (approximately 2 
500,000) compensated for the lower genetic variability of SNPs. Secondly, this study identified 3 
novel genes and thereby new disease mechanisms in a range of diseases including bipolar 4 
disorder and coronary artery disease (CAD) [5,6]. Thirdly, and may be surprisingly, despite the 5 
comprehensive approach in WTCCC, there was failure to discover convincing candidate genes 6 
for other traits including essential (or primary) hypertension in this [5] and other studies [12]. In 7 
light of these developments, numerous reviews and commentaries on the genetic basis of 8 
cardiovascular disease have been published recently [1,13,14]. 9 
Significant progress in cardiovascular genetics can only be optimally achieved by using a 10 
translational approach, since any increase in understanding ultimately depends on knowledge of 11 
pathways and the gene-environment interplay, not heavily considered in single gene-focused 12 
research. This review therefore highlights recent developments in molecular, animal and human 13 
genetics, focusing on a variety of cardiovascular diseases with particular emphasis on 14 
hypertension and the pathophysiological roles of oxidative stress in hypertension. We propose 15 
that future progress in cardiovascular genetic will depend on our ability to understand pathways 16 
and the gene-environment interplay rather than on single gene-focussed research.  17 
 18 
Rodent studies 19 
Recent improvements in rat molecular toolbox have accelerated the identification of genes 20 
involved in complex diseases in the rat, with many of these identified genes showing successful 21 
translation and relevance to human diseases. These experiments in rats mostly relied on 22 
microarray gene expression profiling in biological tissues. However, even with the power of 23 
recent human genome-wide association studies to identify SNPs with genome-wide significance, 24 
it seems likely that to fully elucidate disease mechanisms, model organisms are required. Two 25 
 5 
recent studies using mouse models modified the traditional forward genetic strategy, identifying 1 
the genetic basis from a phenotype, and identified gene networks that contributed to increased 2 
susceptibility to metabolic disease processes in humans such as obesity [15,16]. To date, 3 
essential hypertension has proven particularly resistant to this form of analysis. One further 4 
strategy to overcome limitations of functional genetic studies in humans is to take advantage of 5 
recombinant inbred strains that have been selectively bred over many generations and are 6 
inherently simpler models of disease, where gene expression is modulated while under complex 7 
control of the recipient genetic background [17,18]. This is especially relevant since recent 8 
developments in genome sequencing [19], and software development [20] have accelerated 9 
conserved genome analysis and translational studies between rat, mouse and human [21-23]. 10 
 11 
Rat as a physiological model of human cardiovascular disease 12 
Inbred strains of rodents have been used to study mammalian physiology and understand the 13 
contribution of specific genes to the pathogenesis of many diseases. The stroke-prone 14 
spontaneously hypertension rat (SHRSP), for example, is a well-characterized experimental 15 
model for human essential (or primary) hypertension, i.e. for the far more common polygenic 16 
form of hypertension. Similar to human disease, the genetic determination of hypertension in the 17 
SHRSP model is due to multiple gene-gene and gene-environment interactions [17]. The SHRSP 18 
develops a number of cardiovascular complications, including cardiac hypertrophy, stroke and 19 
endothelial dysfunction due to increased oxidative stress [24-29]. Although exceptionally high 20 
blood pressure is clearly a factor for end-organ damage in the SHRSP, genetic factors are also 21 
likely to contribute. Genome-wide linkage studies have been successful in localizing large 22 
chromosomal regions containing quantitative trait loci (QTL) for blood pressure regulation in the 23 
SHRSP [17]. In particular, two blood pressure QTL have been mapped to rat chromosome 2 24 
[30]. This region of chromosome 2 is a classic example of a common or overlapping QTL, since 25 
 6 
it has been implicated in several rat crosses. These two QTL, therefore, have become a focus for 1 
further congenic strategies in our [31] and other [32,33] laboratories. Speed congenic breeding 2 
protocols have generated strains, introducing various segments of chromosome 2 from the Wistar 3 
Kyoto (WKY) into the SHRSP rat and vice versa [31,34]. Transfer of the region of rat 4 
chromosome 2 containing QTL from WKY into an SHRSP genetic background lowered both 5 
baseline and salt-loaded systolic blood pressure by approximately 20 and 40 mmHg, 6 
respectively, in male congenic rats compared to the SHRSP parental strain (Figure 1). In the 7 
reciprocal WKY.SPGla2a congenic strain the blood pressure was increased by approximately 8 
15mmHg. In combination with congenic strain construction in the SP.WKYGla2a and 9 
SP.WKYGla2c* strains, genome-wide microarray expression profiling identified glutathione S-10 
transferase mu type 1 (Gstm1) as a positional candidate gene for spontaneous hypertension 11 
[23,34,35] and endothelial differentiation gene 1 (Edg1) and vascular cell adhesion molecule 1 12 
(Vcam1) for salt sensitivity [36] (Figure 1, Text Box). 13 
 14 
Candidate gene approach in human studies 15 
In the last few years, exciting developments in rat genetics have integrated a variety of genetic 16 
mapping strategies, gene expression and computational analysis to accelerate gene discovery in 17 
rat cardiovascular disease including those involved in affecting left ventricular mass [37] and 18 
heart failure [38] with important implications for human disease. Robust candidate genes for 19 
human cardiovascular disease have been derived from experimental models such as the SHRSP 20 
and from pathophysiological considerations. For example, sodium homeostasis, oxidative stress 21 
and vascular remodelling are clearly involved in the pathogenesis of hypertension, and genes 22 
involved in these pathways are likely to be genetic candidates for hypertension. It has been 23 
shown without any doubt that GSTM genes are functional and positional candidate genes for 24 
human hypertension and possibly for other cardiovascular diseases (Text Box). Previous to work 25 
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in SHRSP and chromosome 2 congenic strains [34,35], GSTM genes were subject to association 1 
studies in humans [39-41] due to the fundamental role of the oxidative stress pathway in 2 
cardiovascular pathophysiology [42,43]. While there is agreement on the involvement of genetic 3 
variants of GSTMs in the development of cancer [44,45], studies on the role of GSTMs in 4 
cardiovascular diseases are less consistent [40,41]. This inconsistency suggests the necessity for 5 
setting quality criteria for genetic association studies. In fact, such criteria have been recently 6 
published by the National Cancer Institute (NCI) and the National Human Genome Research 7 
Institute (NHGRI) Working Group on Replication in Association Studies; these criteria focus on 8 
the importance of replicating significant results in independent cohorts and demonstrating 9 
differential gene expression and functional analysis of genetic variants [46]. In accordance with 10 
these criteria, a definitive association study of GSTMs in hypertension has been conducted, 11 
associating a SNP in GSTM5 with hypertension in a family-based cohort and differential 12 
expression of GSTM5 in renal tissue of subjects with hypertension compared to normotensive 13 
controls. [47] However, these findings were not reproduced in an independent case-control 14 
cohort. Although this study linking GSTM5 with hypertension is essentially negative, it 15 
demonstrates the need for replication despite the presence of functional or gene expression data. 16 
Variants of other genes have been more consistently found to be associated with cardiovascular 17 
disease. For example, studies have attempted to identify candidate genes for essential 18 
hypertension by extrapolating knowledge of the pathogenesis of monogenic forms of 19 
hypertension. A recent study in the general population, i.e. in a cohort not enriched for 20 
hypertension, suggests an association of variants in such genes including KCNJ1, encoding the 21 
potassium channel ROMK1, with the level of blood pressure [48] (Text Box). Many rare alleles 22 
that alter renal salt handling in blood pressure variation have also been identified in the 23 
Framingham Heart Study [49]. However, these results must be interpreted with caution, as the 24 
 8 
functional or molecular link between polymorphisms and changes in gene and protein expression 1 
have not yet been examined in these studies.  2 
Robust evidence associates WNK1 and WNK4 genes, encoding serine-threonine kinases and 3 
involved in renal electrolyte homeostasis, with the level of blood pressure in a general population 4 
sample and in patients with severe hypertension [50,51] (Text Box). With regard to the oxidative 5 
stress pathway, variants of CYBA encoding the p22phox subunit of NADPH oxidase have been 6 
found to be associated with hypertension [52], vascular superoxide production [53,54], and 7 
intermediate cardiovascular phenotypes such as increased carotid intima-media thickness and 8 
vascular stiffness [54,55] (Text Box). Consistent association of a genetic variant and the 9 
immediate function of its gene product affecting a cardiovascular trait and intermediate 10 
phenotypes provides strong evidence for a functional role of that gene in the pathophysiology of 11 
cardiovascular disease. Other promising functional candidate genes for cardiovascular disease 12 
include ACE and ADD1, which encode for proteins that are critically involved in 13 
pathophysiology of hypertension such as the renin-angiotensin-aldosterone system and Na+/K+ 14 
ATPase activity [reviewed in 56,57] (Text Box), but they did not produce significant signals in 15 
recent genome-wide scans [5,6,12]. 16 
 17 
Genome-wide association studies in human cardiovascular disease 18 
In contrast to candidate gene studies, GWAS initially are not hypothesis-driven, i.e. they are not 19 
necessarily suited to detect an association of well-established candidate genes with 20 
cardiovascular disease, since the effect of even strong candidate genes might be relatively low or 21 
not detectable if only a limited set of phenotypes are examined. The major challenge in GWAS is 22 
therefore to provide adequate power to detect disease-specific genetic variants [58]. Factors 23 
influencing power and sample size determinants include expected effect size, the degree of gene-24 
gene and gene-environment interactions, and the number of genetic variants that are necessary to 25 
 9 
cause disease. In most cardiovascular traits, we assume involvement of several, maybe hundreds 1 
of genes with individual odds ratios of 1.2-1.3 or less [1]. Current GWAS are powered according 2 
to this assumption, and the promising results of GWAS in CAD and diabetes [5,6,11] confirm 3 
the validity of these considerations. 4 
Interpreting GWAS results that do not result in significant associations of genetic variants with 5 
disease is challenging. For example, the lack of significant associations of SNPs with 6 
hypertension in the WTCCC and the British Genetics of Hypertension (BRIGHT) study [59, 12] 7 
[5] triggered discussions about genetics of cardiovascular diseases. However, a negative GWAS 8 
does not exclude involvement of genetic factors in the pathogenesis of, for example, 9 
hypertension. In fact, family and twin studies have established that genetic factors are important 10 
determinants of hypertension [1]. A negative result is more likely due to wrong assumptions with 11 
regard to effect size and number of potentially involved genes. In this sense, GWAS are not 12 
completely hypothesis-free but instead dependent on a hypothesis of effect sizes and number of 13 
genes and pathways potentially involved. 14 
 15 
The role of phenotyping in genetic studies 16 
Recent advances in genotyping technology yielded increasingly robust genotyping procedures . 17 
Therefore, the chance to find significant associations between genetic variants and a specific 18 
phenotype increasingly depends on the quality of phenotyping. A clearly defined and measurable 19 
phenotype increases the chances for detecting genotype-phenotype associations. For example, 20 
the extremely strong association (up to P=4.95 x 10-10) found between complement factor H gene 21 
(CFH) variants such as rs380390 or Tyr-402His and age-related macular degeneration [60,61] 22 
not only depended on the extraordinarily strong gene effect but also on the clear detection of 23 
presence of the phenotype. In other words, investigators were sure that all cases had macular 24 
degeneration whereas all control subjects clearly did not have macular degeneration. 25 
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In cardiovascular diseases, phenotyping is more challenging. For example, it is difficult to 1 
uniformly define the phenotype "stroke" in patients with a cerebrovascular event, as this 2 
phenotype may range from modest to severe extremes, e.g. from ischaemic to haemorrhagic 3 
stroke, from transient ischaemic attacks to established cerebral infarction, and from small 4 
infarcted areas to areas involving large parts of the brain. Additional phenotypes can be observed 5 
depending on the mode of imaging; for example, in comparison to computed tomography, 6 
magnetic resonance imaging more sensitively detects the penumbra that is also part of the 7 
phenotype "stroke". Unsurprisingly, GWAS addressing stroke have so far only produced 8 
preliminary results and are one of the major challenges in cardiovascular genetics [62,63]. It is 9 
also difficult to define a uniform phenotype in CAD patients for genetic studies. It is even more 10 
difficult to definitely exclude presence of CAD in controls, since such an exclusion would rely 11 
on invasive techniques that are clearly unethical in presumably healthy subjects. This potential 12 
"caseness" of controls has to be considered in power and sample size calculations of genetic 13 
studies [5].  14 
In contrast to the phenotypes of stroke and CAD, hypertension can be diagnosed qualitatively 15 
and quantitatively with high precision using non-invasive techniques at low cost and without 16 
potentially harmful imaging techniques involving radiation. Nevertheless, only few genetic 17 
studies on hypertension have benefited from accurate phenotyping which should ideally include 18 
standardized office blood pressure readings in the absence of antihypertensive medication and 19 
24-hour ambulatory blood pressure monitoring in both cases and controls. The fact that WTCCC 20 
did not find significant genetic associations for hypertension [5] is at least in part attributable to 21 
the lack of precise blood pressure phenotyping in control subjects [1]. Nevertheless, the WTCCC 22 
[5] and BRIGHT study [12] benefit by selecting cases at the top end of the blood pressure 23 
distribution in a given population, since selecting extreme phenotypes increases the chance of 24 
finding a genetic determinant. In our opinion, selecting extreme phenotypes, however, should 25 
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also be done for control subjects. In the first instance control subjects should undergo the same 1 
phenotyping as cases. In the case of hypertension for example, one would expect at least the 2 
same protocols for blood pressure measurement being applied to cases and controls. Ideally, 3 
however, control subjects would not only be "not hypertensive", but in fact should have normal 4 
blood pressure, for example 120/70 mmHg (and not for example, high normal blood pressure 5 
such as 135/85 mmHg). One could also ask for further evidence of absence of cardiovascular 6 
disease in control subjects, such as absence of end organ damage including hypertensive 7 
retinopathy, microalbuminuria and left ventricular hypertrophy, and follow-up data without 8 
evidence for cardiovascular events. We think that this concept of well characterised and 9 
"absolutely normal" control subjects ("hypercontrols") will increase the chances of finding 10 
genetic associations by increasing the phenotypic difference between cases and controls in 11 
hypertension and other cardiovascular diseases. 12 
Increasing phenotype stringency also facilitates the determination of pathophysiological links 13 
between genes and cardiovascular traits. For example, assessing inflammatory markers at the 14 
time of blood pressure measurement could help confirm the functional relevance of any 15 
establishd genetic associations.  Indeed, GWAS has been successful in identifying biomarkers 16 
such as lipids [9-11] and urate levels [10] in patients with diabetes and cardiovascular disease.  17 
In most cases, the original study may not have been powered for studies into additional 18 
phenotypes, and such data must then be derived from secondary analyses. The more phenotypes 19 
and subphenotypes/ intermediate phenotypes measured, the greater the risk for false positive 20 
findings when these phenotypes are subject to genetic association studies using the same genetic 21 
markers [64]. Therefore, while detailed characterisation of additional and intermediate 22 
phenotypes are suggested, it may benefit researchers to focus on the precise characterisation of 23 
the primary phenotype. In that sense, a study into the genetics of hypertension would benefit 24 
 12 
more from a second blood pressure reading than from measurement of an inflammatory marker 1 
e.g., C-reactive protein. 2 
 3 
Pathways versus single gene effects 4 
The stringent criteria for significance in GWAS are somehow artificial, as they primarily derive 5 
from the view that a single gene is entirely responsible for the resulting phenotype. It is more 6 
likely that genes and their gene products interact with each other and with environmental factors 7 
in highly redundant pathways to contribute to a phenotype. As previously discussed, a recent 8 
study excluded the significant association between GSTM genes and hypertension in humans 9 
[47], but other studies have shown significant effects of GSTM genotype in the presence of 10 
mutations of other GST genes [65]. With GST enzymes being involved in detoxification of free 11 
radicals, it is likely that mutations in more than one GST gene are required to cause a certain 12 
phenotype, as other enzymes could compensate for one dysfunctional gene product. It is also 13 
possible that mutations only in the presence of free radicals, e.g. derived from smoking or other 14 
toxins, will lead to a phenotype, as under normal conditions even dysfunctional enzymes could 15 
cope with the amount of free radicals generated. While some studies may be underpowered to 16 
examine such complex interactions, it is possible that even though two or three genetic variants 17 
within the same pathway show association with a phenotype at only borderline significance, 18 
these genes may be as relevant to pathogenesis as a single genetic variant in the same pathway 19 
with a highly significant P-value (Table 1). 20 
Current studies on the genetics of cardiovascular disease are performed by large consortia of 21 
researchers on thousands of patient samples. It is now common practice that patient and control 22 
cohorts are "reshuffled" and subject to more than one study. For example, the cases in the 23 
WTCCC [5] derive from existing cohorts and have been analysed using different genotyping 24 
technology and/or different control subjects in the past [12,50]. While the detailed statistical 25 
 13 
implications of this practice are beyond the scope of this review, the amount of available 1 
genotypic and phenotypic data in publicly accessible databases constitutes an enormously rich 2 
resource of data. Even within a single study such as the WTCCC [5], researchers are able to 3 
access data and investigate the association of genetic variants across a variety of cardiovascular 4 
and other diseases. Such comparisons offer additional information about significance of results. 5 
Table 1 shows that certain genes are involved in a number of diseases that are expected to share 6 
the same pathogenetic pathways, e.g. CAD and rheumatoid arthritis in both of which 7 
inflammation plays a role in the disease process. Even if associations are only of nominal 8 
significance, occurrence of associations between genotype and phenotype in more than one 9 
disease points towards a "true" finding. However, biostatistical methods still need to be 10 
developed to make use of such information, as our current abilities to analyse large datasets of 11 
mainly descriptive nature are limited. It is clear that such analysis would only be suitable to 12 
generate hypotheses, but the extent of any validation and replication studies needs to be 13 
evaluated. 14 
 15 
Current and future trends in cardiovascular genetics 16 
The dramatic improvement in genotyping technology constitutes a unique opportunity to conduct 17 
large-scale collaborative studies on the genetics of cardiovascular disease. Standardisation of 18 
phenotyping and quality control is a prerequisite for interpretation but also offers the possibility 19 
of pooling of datasets from different investigators in order to create larger cohorts. Also, only if 20 
genetic studies follow similar quality criteria, there is potential for meta-analysis of results of 21 
different studies. The vast majority of genetic studies are currently performed in case-control 22 
settings, primarily aimed at transmission of disease alleles that can be ideally assessed in family-23 
based studies [66]. Large-scale genotyping and the presence of complex pathophysiological 24 
networks, however, demands new biostatistical methods to analyse the datasets. At present, it 25 
 14 
seems that advances in genotyping technology run at a faster pace than development of analysis 1 
methods, with an urgent need for development of new statistical and mathematical tools. 2 
Recent trends in genetics and epigenetics will play a major role for genetic studies of 3 
cardiovascular disease within the next few years. For example, sub-microscopic re-arrangements 4 
of small fragments of DNA (copy number variation) have not yet been examined in genotyping 5 
studies but are believed to play an important role in overall genetic variation and possibly in 6 
pathophysiology of cardiovascular and other diseases [67]. Also, epigenetic mechanisms, 7 
including regulation by microRNAs, cause differential gene activity in the absence of DNA 8 
mutation [68]. These will be exciting targets for future studies. Finally, high-throughput 9 
technology is now also available for analyzing protein expression, and proteomics approaches 10 
will open new avenues of cardiovascular research [69,70]. All these recent trends will contribute 11 
to the impact of genetic research on treatment and prevention of cardiovascular disease. First 12 
steps into cardiovascular pharmacogenomics have been made [71-73], and evolving technologies 13 
give confidence that many more such steps will follow in the near future. 14 
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Text Box. Pathomechanisms of hypertension. 
 
Electrolyte homeostasis 
Impaired renal sodium and potassium balance is one of the most important factors in the 
development of hypertension. The renin-angiotensin-aldosterone system plays a crucial role in 
this context. Monogenic forms of hypertension are characterized by mutations of genes that are 
involved in renal electrolyte transport and recent data suggest that variants in these genes could 
also contribute to the pathogenesis of essential (primary) hypertension. 
• Adducin is a cytoskeleton protein that is associated with binding of the Na+/K+ ATPase to 
the cytoskeleton. Variants of the ADD1 gene have been shown to stimulate Na+/K+ 
ATPase, therby leading to sodium retention and hypertension [56,57].  
• WNK1 and WNK4 are serin-threonine proteases expressed in the distal nephron. 
Mutations in WNK1 and WNK4 genes have been shown to be associated with high blood 
pressure [50,51]. 
• ROMK1 is an inwardly rectifying potassium channel. Mutations in the KCNJ1 gene 
cause a form of Bartter syndrome, a monogenic form of hypertension. Recently, variants 
of KCNJ1 have been found to be associated with essential (primary) hypertension [48]. 
Vascular function and structure 
Changes in vascular function and structure are found early in the development of hypertension 
and other cardiovascular diseases and are both cause and consequence of disease, particularly 
with regard to end organ damage including coronary artery disease and nephropathy. 
• Endothelial differentiation gene 1 encodes a G-protein-coupled receptor and is highly 
expressed in endothelial cells. It is involved in endothelial cell differentiation and causes 
cell-cell adhesion. In rat, Edg1 is a functional and positional candidate gene for 
hypertension [36]. 
• Vascular cell adhesion molecule 1 is a cell surface sialoglycoprotein that is expressed by 
activated endothelium. It mediates leukocyte-endothelial cell adhesion and is 
implemented in the pathogenesis of atherosclerosis. In rat, Vcam1 is a functional and 
positional candidate gene for hypertension [36]. 
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Oxidative stress 
Oxidative stress is an imbalance between production of reactive oxygen species such as 
superoxide anion and defences against these free radicals. Excess of free radicals causes damage 
to proteins, lipids and DNA and leads to changes in vascular function and structure. One of the 
earliest measurable consequences of oxidative stress in humans is impaired endothelium-
dependent vasodilation, a common finding in cardiovascular diseases. 
• NAD(P)H oxidase is a membrane-bound enzyme complex and a major source of vascular 
superoxide generation. Polymorphisms in the CYBA gene encoding the p22phox subunit 
of NAD(P)H oxidase have been associated with increased superoxide production and 
essential hypertension [52-55]. 
• Glutathione S-transferases are involved in the detoxification of a number of endogenous 
and exogenous compounds. Amongst the classes of GST enzymes the mu class is 
particularly involved in detoxification of free radicals. GSTM enzymes protect against 
oxidative stress, and or reduced expression of Gstm1 has been found to be associated 
with hypertension in rats [23,34,35]. 
 
This text box shows major mechanisms but is by no means a comprehensive overview of the 
pathogenesis of hypertension. The genes in the text box have been selected as examples and are 
also mentioned in the text and many other genes are involved in these pathways. For further 
reading see [1,13,14]. 
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Table 1 
 
Gene Chromosome BD CAD CD HTN RA T1D T2D 
CRP 1 0.33489 0.179421 0.395047 0.288228 0.0653446 0.0758595 0.160982 
GSTM3 1 0.798069 0.13995 0.342538 0.419983 0.823041 0.949932 0.546322 
IL6R 1 0.0448555 0.00182706 0.001376 0.0600474 0.00142976 0.00851496 0.0265767 
IL1B 2 0.288579 0.564475 0.341337 0.872045 0.254369 0.333314 0.163601 
SOD3 4 0.223077 0.192229 0.0601649 0.106382 0.363473 0.0163271 0.0185113 
IL6ST 5 0.949803 0.813763 0.889323 0.771115 0.657419 0.473425 0.921231 
SOD2 6 0.0915653 0.000536518 0.0683838 0.291131 0.00459882 0.162744 0.175661 
NOS3 7 0.739966 0.947511 0.328744 0.664842 0.551039 0.83784 0.909137 
PON1 7 0.274734 0.139083 0.0830213 0.0205941 0.0485964 0.0258393 0.0774826 
PON2 7 0.079956 0.205913 0.0277005 0.0363002 0.0118318 0.224679 0.0569649 
PON3 7 0.421571 0.319962 0.210634 0.177386 0.412726 0.241487 0.0790662 
GSR 8 0.398653 0.0793362 0.62712 0.185672 0.325371 0.0590146 0.400362 
CAT 11 0.316104 0.0251473 0.364005 0.215003 0.384584 0.15847 0.365068 
NOS1 12 0.012322 0.0983362 0.10515 0.0239134 0.331539 0.396458 0.36203 
CYBA 16 0.659232 0.635098 0.554587 0.440936 0.785349 0.782325 0.388056 
MPO 17 0.05805 0.236249 0.410893 0.0517084 0.131433 0.154636 0.331649 
NOS2A 17 0.0840542 0.0568331 0.0139903 0.0731338 0.210996 0.0236865 0.0512084 
KLK1 19 0.110755 0.293647 0.654226 0.0160403 0.452522 0.0685839 0.035118 
GSS 20 0.0122597 0.186009 0.195624 0.178708 0.0194835 0.259212 0.43203 
HMOX1 22 0.381948 0.876874 0.207927 0.133741 0.398465 0.967978 0.302908 
 
Comparison of most-significant oxidative stress/inflammatory pathway gene-centric hits from 
the Wellcome Trust Case Control Consortium (WTCCC) study across the range of disease 
phenotypes studied. 
P-values were downloaded from the WTCCC website (www.wtccc.org.uk) for the seven 
common diseases investigated (BD, bipolar disorder; CAD, coronary artery disease; CD, Crohn's 
disease; HTN, hypertension; RA, rheumatoid arthritis; T1D, type 1 diabetes; T2D, type 2 
diabetes) [5]. Light grey shading indicates P<0.05, dark grey shading indicates P<0.005. 
This approach highlights that even in the absence of genome-wide significance levels, there are 
patterns of nominal significance across different diseases that can advise and direct further 
pathway-directed search for causative genes. For example, nominal significance of interleukin-6 
receptor gene (IL6R) in most diseases highlights the crucial importance of this gene in the 
pathophysiology of a number of disorders. Mitochondrial superoxide dismutase gene (SOD2) is 
associated with CAD and RA. In both diseases, reactive oxygen species play a particularly 
strong role. Absence of nominal significance for SOD2 in BD, in which oxidative stress is 
thought to play a less prominent role, is supportive of these data. Absence of any significant 
results for p22phox subunit of NADPH oxidase (CYBA) is more difficult to interpret, but the fact 
that there was no nominal significance in any of the disorders indicates that this may be a less 
important member of the disease causing pathway. 
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Figure Legends 
 
Figure 1. Chromosome 2 genetic map and congenic substrains generated on the SHRSP 
genetic background. 
The bars represent chromosome 2 genotypes for each of the congenic substrains. Dark grey bars 
indicate regions of Wistar-Kyoto (WKY) homozygosity. Lighter grey bars represent regions of 
stroke-prone spontaneously hypertensive rat (SHRSP) homozygosity. The various introduced 
WKY regions completely overlap the original SP.WKYGla2a congenic interval. For each 
substrain, averaged difference in baseline and salt-loaded systolic blood pressure compared to 
SHRSP, measured by radiotelemetry, is illustrated below their respective genotype. 
SP.WKYGla2a n=8, SP.WKYGla2c* n=12, SP.WKYGla2b n=6, SP.WKYGla2e n=8, 
SP.WKYGla2f n=8, SP.WKYGla2g n=5, SP.WKYGla2i n=5, SP.WKYGla2k n=7.  
* P<0.05 compared to baseline and salt-loaded systolic blood pressure respectively, in male 
SHRSP using a linear mixed effects model. cM denotes centi Morgan, and Mb denotes 
megabases. 
Further analysis showed that glutathione S-transferase mu type 1 (Gstm1), endothelial 
differentiation gene 1 (Edg1) and vascular cell adhesion molecule 1 (Vcam1) are candidate genes 
for hypertension and salt sensitivity, respectively. Position of these genes is indicated in the 
figure. Salt sensitivity was studied to specifically dissect genes that are involved in sodium 
homeostasis, which is one of the major pathogenetic mechanisms of hypertension.  
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Figure 2. Translational approach in candidate gene studies. 
Translation from genetic findings in rodents to human genetics is illustrated by studies on 
Glutathione S-transferase mu type 1 (Gstm1) in hypertension. 
(A) A genome-wide scan in crosses of Wistar-Kyoto (WKY) and stroke-prone spontaneously 
hypertensive rat (SHRSP) revealed two quantitative trait loci (QTLs) for hypertension on rat 
chromosome 2 [30]. (B) Congenic strains have been designed replacing parts of chromosome 2 
of SHRSP with parts of WKY chromosome 2 [31]. These strains were used confirm the effect of 
QTLs on the phenotype hypertension. (C) Microarray analysis showed differential expression of 
Gstm1 between WKY, SHRSP and the congenic strain SP.WKYGla2c* with the congenic strain 
exhibiting similar Gstm1 expression as WKY [34,35]. (D) Pathway analysis shows a crucial role 
of Gstm1 in detoxification of free radicals (X) by transferring them to glutathione (GSH). The 
figure is simplified, but still illustrates the complexity of the GSH pathway which can also be 
affected by variations of other genes. (E) Analysis of conserved synteny between rat 
chromosome 2 and human chromosome 1 showed five potential human orthologues of rat 
Gstm1. (F) These orthologues, GSTM1 to GSTM5, were then subject to genetic association and 
linkage studies in humans [47]. 
The same approach can be applied to other cardiovascular traits and other candidate genes. 
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